1. Introduction {#sec1-antibiotics-09-00514}
===============

Carbapenem resistance poses a significant threat to public health globally. It occurs mainly among gram-negative bacteria such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, which are the most concerning bacteria with a propensity toward multi-drug resistance and cause the life-threatening healthcare associated infections amongst critically ill and immunocompromised individuals \[[@B1-antibiotics-09-00514]\]. Carbapenem resistant *K. pneumoniae* (CRKP), *P. aeruginosa* (CRPA), and *A. baumannii* (CRAB) were recognized as critical-priority bacteria, by the World Health Organization (WHO), which was mainly based on the associated increasing clinical and economic burden, unavailability of effective therapy, and antibiotic resistant characteristics \[[@B2-antibiotics-09-00514]\].

In the European countries, the population-weighted mean proportions of CRKP, CRPA, and CRAB were 7.5%, 17.2%, and 31.9% in 2018, respectively \[[@B3-antibiotics-09-00514]\]. In China, there were marked increases in the proportion of CRKP from 3.0% in 2005 to 26.3% in 2018, and in the prevalence of CRAB from 39.0% in 2005 to 73.9% in 2018. The proportion of CRPA showed a downward trend during between 2005 and 2014, but deteriorated from 2015 and reached 30.7% in 2018 \[[@B4-antibiotics-09-00514],[@B5-antibiotics-09-00514],[@B6-antibiotics-09-00514],[@B7-antibiotics-09-00514],[@B8-antibiotics-09-00514]\].

Recently published studies mainly focus on gram-positive bacteria \[[@B9-antibiotics-09-00514]\], while only few studies estimated the burden of CRKP, CRPA, and CRAB in terms of mortality, length of stay (LOS), and cost \[[@B10-antibiotics-09-00514],[@B11-antibiotics-09-00514],[@B12-antibiotics-09-00514],[@B13-antibiotics-09-00514],[@B14-antibiotics-09-00514]\]. It was reported that patients with CRKP, CRPA, and CRAB infections were associated with higher mortality, longer hospital stay, and higher hospital costs compared with carbapenem susceptible cases \[[@B9-antibiotics-09-00514],[@B15-antibiotics-09-00514],[@B16-antibiotics-09-00514],[@B17-antibiotics-09-00514]\]. In addition, hospital costs incurred by colonized patients with CRKP were also high \[[@B18-antibiotics-09-00514]\]. However, it was also found that there were no significant differences in hospital mortality between CRPA and carbapenem susceptible *P. aeruginosa* (CSPA) cases \[[@B10-antibiotics-09-00514],[@B15-antibiotics-09-00514]\], in total hospital cost between CRAB and carbapenem susceptible *A. baumannii* (CSAB) cases \[[@B14-antibiotics-09-00514]\].

In China, there were some studies exploring the mortality and LOS associated with CRKP \[[@B19-antibiotics-09-00514],[@B20-antibiotics-09-00514],[@B21-antibiotics-09-00514],[@B22-antibiotics-09-00514],[@B23-antibiotics-09-00514]\], CRPA \[[@B24-antibiotics-09-00514],[@B25-antibiotics-09-00514],[@B26-antibiotics-09-00514]\], or CRAB \[[@B27-antibiotics-09-00514],[@B28-antibiotics-09-00514],[@B29-antibiotics-09-00514],[@B30-antibiotics-09-00514]\], and exploring the economic burden attributed by CRKP \[[@B19-antibiotics-09-00514]\], CRPA \[[@B24-antibiotics-09-00514]\], or CRAB \[[@B27-antibiotics-09-00514],[@B31-antibiotics-09-00514]\]. Although hospitalized patients with carbapenem resistance appeared to have increased hospitality mortality, hospital stay, and hospital costs, no significant differences in hospital mortality and hospital stay between CRKP and carbapenem susceptible *K. pneumoniae* (CSKP) cases were showed as well \[[@B19-antibiotics-09-00514],[@B21-antibiotics-09-00514]\]. In addition, majority of studies were conducted in a single hospital setting, and using univariate analyses regardless of confounding risk factors \[[@B32-antibiotics-09-00514]\]. Therefore, there are limited published data and the clinical and economic impacts of CRKP, CRPA, and CRAB remain largely uninvestigated in China. In this study, we aimed to examine the clinical and economic burden of carbapenem resistance in *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* compared with carbapenem susceptible cases in China.

2. Material and Methods {#sec2-antibiotics-09-00514}
=======================

2.1. Study Site {#sec2dot1-antibiotics-09-00514}
---------------

This study was conducted in four tertiary hospitals in China. Hospital site 1 and site 2 are general provincial hospitals in Zhejiang province and Shandong province, respectively. Hospital site 3 and site 4 are general county hospital and combined traditional Chinese and Western medicine provincial hospital in Zhejiang province, respectively. Hospital site 1--4 are with 3200, 3500, 1727, 2100 of hospital beds, and with 170,000, 160,000, 80,000, 50,000 of inpatients per year, respectively.

2.2. Study Design and Patients {#sec2dot2-antibiotics-09-00514}
------------------------------

It was a retrospective and multicenter study. Patients were identified from the records of the clinical microbiology laboratory. 100% of inpatients in hospital site 2--4, and 60% of inpatients in hospital site 1 between 2013--2015 who had clinical samples positive for CRKP, CRPA, CRAB infection or colonization were included. The control group comprised of patients with CSKP, carbapenem susceptible *P. aeruginosa* (CSPA), and CSAB-positive clinical samples with the same percentages who were hospitalized during the same study period. Only 60% of inpatients were randomly selected from hospital site 1 due to the large inpatient population \[[@B31-antibiotics-09-00514]\]. The interpretation of carbapenem susceptibility was based on the Clinical and Laboratory Standards Institute (CLSI) definitions and reported as resistant (R), susceptible (S), and intermediate (I). *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* isolates, were considered resistant to carbapenems if they were resistant or intermediate to any carbapenem (imipenem, meropenem, panipenem or ertapenem) \[[@B31-antibiotics-09-00514]\], and the control group was defined as patients infected or colonized by *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* susceptible to all carbapenems. To avoid duplication, cases with the first episode detected in any clinical specimen (e.g., blood, stool, cervical, urethral sources) were included. If multiple samples were taken from a patient during the study period, only the first sample was included in this study.

2.3. Data Collection {#sec2dot3-antibiotics-09-00514}
--------------------

Data were obtained from patients' medical records. Patients' characteristics included demographics (age, sex, and insurance), comorbidities (disease diagnosis, and Charlson comorbidity index (CCI), hospital events (admitting service, surgical services, and dates of hospital and intensive care unit (ICU) admission/discharge), and clinical outcomes (discharged alive or death during hospitalization). We also noted any related laboratory results when isolation of *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* was recorded in the inspection system, and recorded the antibiotic susceptibility test results obtained from the microbiology laboratory. In addition, economic costs associated with these patients were obtained from the financial system. The economic costs included total hospital cost, medication cost (antibiotic cost), diagnostic cost, treatment cost, material cost, and other costs, including out-of pocket payment and payment covered by health insurers. Values of the economic costs were converted from Chinese Yuan to United States dollars in 2015 \[[@B33-antibiotics-09-00514],[@B34-antibiotics-09-00514]\].

2.4. Propensity Score Matching {#sec2dot4-antibiotics-09-00514}
------------------------------

To eliminate the impact of potential confounding variables, propensity score matching (PSM) with 1:1 nearest-neighbor matching using STATA was conducted. For logistic regression modeling with carbapenem resistant and carbapenem susceptible as dependent variables, independent variables included age, sex, insurance, number of diagnosis, CCI, admission to ICU, surgery, and comorbidities, but not clinical and economic outcomes (economic costs, LOS, and in-hospital mortality). The generated pairs, who were matched for all included variables, were subjected to further analyses of economic costs, LOS, and in-hospital mortality.

2.5. Indicators and Statistical Analyses {#sec2dot5-antibiotics-09-00514}
----------------------------------------

In this study, the main indicators included economic costs, LOS, and in-hospital mortality. We performed 1000 iterations of Monte Carlo simulations to calculate the 95% uncertainty interval for each indicator with normal distribution using SAS \[[@B35-antibiotics-09-00514]\]. We compared the main indicators between CRKP and CSKP group, between CRPA and CSPA group, between CRAB and CSAB group using *t* test and χ^2^ test for quantitative and qualitative variables, respectively. All *p*-values were two-tailed, \<0.05 were deemed statistically significant, and ≥0.05 and \<0.10 were considered marginally significant.

2.6. Ethical Approval and Informed Consent {#sec2dot6-antibiotics-09-00514}
------------------------------------------

The study was approved by the institutional review board of Zhejiang University School of Public Health, who waived the need for informed consent. All inpatients data were anonymized prior to analysis.

3. Results {#sec3-antibiotics-09-00514}
==========

We included 12,022 inpatients infected or colonized with *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* between 2013 and 2015, including 5159 *K. pneumoniae*, 3918 *P. aeruginosa*, and 2945 *A. baumannii*. Of these, a total of 831 with CRKP and 4328 with CSKP, 1244 with CRPA and 2674 with CSPA, 1665 with CRAB and 1280 with CSAB were included. Significant differences were found in insurance, admission to ICU, surgery between CRKP and CSKP group, in age, sex, number of diagnosis, CCI, admission to ICU between CRPA and CSPA group, in age, sex, insurance, number of diagnosis, CCI, admission to ICU, surgery between CRAB and CSAB group. Some comorbidities between the three groups were significantly different as well. After PSM, there were no differences in patients' characteristics between the three groups, and generated 822 pairs, 1155 pairs, and 682 pairs, respectively ([Table 1](#antibiotics-09-00514-t001){ref-type="table"}, [Table 2](#antibiotics-09-00514-t002){ref-type="table"} and [Table 3](#antibiotics-09-00514-t003){ref-type="table"}).

Inpatients with carbapenem resistance were significantly associated with higher economic costs than carbapenem susceptible cases. For patients with *K. pneumoniae*, the mean differences (95% UI) in total hospital cost, antibiotic cost, medication cost including antibiotics, diagnostic cost, treatment cost and material cost were \$14,251 (\$13,852--\$14,653), \$3296 (\$3202--\$3390), \$9132 (\$8910--\$9354), \$1517 (\$1465--\$1570), \$2574 (\$2462--\$2686), and \$899 (\$826--\$971), respectively ([Table 4](#antibiotics-09-00514-t004){ref-type="table"}). For patients with *P. aeruginosa*, the mean differences (95% UI) in economic costs were \$4,605 (\$4249--\$4960), \$1078 (\$1007--\$1149), \$3053 (\$2867--\$3238), \$370 (\$323--416), \$1174 (\$1043--\$1305), and \$76 (\$19--\$132), respectively ([Table 5](#antibiotics-09-00514-t005){ref-type="table"}). For patients with *A. baumannii*, the mean differences (95% UI) in economic costs were \$7277 (\$6897--\$7657), \$1537 (\$1468--\$1605), \$3902 (\$3731--\$4074), \$628 (\$585--\$670), \$2156 (\$1967--\$2344), \$421 (\$351--\$491), respectively ([Table 6](#antibiotics-09-00514-t006){ref-type="table"}).

Compared with inpatients with CSKP, CSPA, and CSAB, those with CRKP, CRPA, and CRAB were significantly associated with longer LOS, with mean differences (95% UI) of 13.2 days (12.7--13.7days), 5.4 days (4.4--6.5 days), and 15.8 days (13.9--17.7 days), respectively ([Table 7](#antibiotics-09-00514-t007){ref-type="table"}).

There were statistical differences in in-hospital mortality rate between CRKP and CSKP group (9.59% (9.33--9.85%) vs. 6.65% (6.43--6.87%)), and CRAB and CSAB group (8.28% (8.04--8.53%) vs. 4.25% (4.07--4.43%)). The difference in in-hospital mortality rate between CRPA and CSPA group was marginal significant, with the difference rate of 2.03% (1.75--2.32%) (*p* = 0.052) ([Table 8](#antibiotics-09-00514-t008){ref-type="table"}).

4. Discussion {#sec4-antibiotics-09-00514}
=============

To the best of our knowledge, this is the first large and multicenter study quantifying the clinical and economic impact of CRKP, CRPA, and CRAB in mainland China using the PSM method. We found that after PSM, compared with carbapenem susceptible cases, those with CRKP, CRPA, and CRAB were associated with significantly increased economic costs, excess LOS, and attributable in-hospital mortality rate. A marginal difference in hospital mortality rate existed between CRPA and CSPA group.

It was clearly demonstrated that economic costs for infection or colonization caused by carbapenem resistance were higher than in case of carbapenem susceptible bacteria, suggesting that carbapenem resistance indeed incurs excessive economic costs on patients infected or colonized with *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii*. It also shows that the impact of carbapenem resistance on economic costs might depend on the type of gram-negative bacteria, with resistance in *K. pneumoniae* having a larger impact, followed by *A. baumannii* and *P. aeruginosa*. This finding is consistent with several previous studies, in which carbapenem resistance was associated with higher economic costs for infection or colonization caused by gram-negative bacteria, including *K. pneumonia* \[[@B19-antibiotics-09-00514]\], *P. aeruginosa* \[[@B10-antibiotics-09-00514],[@B12-antibiotics-09-00514],[@B24-antibiotics-09-00514]\], and *A. baumannii* \[[@B11-antibiotics-09-00514],[@B13-antibiotics-09-00514],[@B27-antibiotics-09-00514],[@B31-antibiotics-09-00514]\]. However, one study did not find a statistically significant association in total hospital cost among infants with ventilator associated pneumonia in the ICU between CRAB and CSAB group \[[@B14-antibiotics-09-00514]\], which might be because that critical illness can attenuate the effect of carbapenem resistance \[[@B36-antibiotics-09-00514]\]. Effective control of carbapenem resistance would result in cost savings and could be useful for assessing the cost-effectiveness of interventions to reduce the development and spread of carbapenem resistance in hospital settings \[[@B19-antibiotics-09-00514]\].

We indeed found that carbapenem resistance was associated with longer LOS, which is similar with other investigations that patients with resistant bacteria requires increases in the number of hospitalization days \[[@B19-antibiotics-09-00514],[@B24-antibiotics-09-00514],[@B37-antibiotics-09-00514]\]. Prolonged LOS associated with carbapenem resistance might be independent of the type of gram-negative bacteria, with resistance in *A. baumannii* having a larger influence, followed by *K. pneumoniae*, and *P. aeruginosa*. Hospital stay is the major contributor to the additional economic costs in carbapenem resistant infection or colonization, as patients with longer hospital stay were associated with more antibiotic therapy and more surgeries \[[@B19-antibiotics-09-00514],[@B24-antibiotics-09-00514],[@B37-antibiotics-09-00514]\]; therefore, LOS was not included in PSM analyses \[[@B38-antibiotics-09-00514]\].

The poorest clinical outcomes were observed for CRAB, followed by CRKP and CRPA. In-hospital mortality rate was significantly higher for patients with CRKP and CRAB than for carbapenem susceptible cases, which is similar with other studies \[[@B16-antibiotics-09-00514],[@B39-antibiotics-09-00514],[@B40-antibiotics-09-00514]\]. A 2.03% increase in mortality rate for the CRPA patients is clinically meaningful, and the non-significant *p*-value (*p* = 0.052) is too low to confidently rule out an effect of CRPA on mortality rate, which is different with other findings \[[@B16-antibiotics-09-00514],[@B39-antibiotics-09-00514],[@B40-antibiotics-09-00514]\], however, several studies reported non-significant association between mortality and CRPA as well \[[@B10-antibiotics-09-00514],[@B15-antibiotics-09-00514]\]. Spending on medical services was associated with a reduction in the mortality rate, therefore, it is critical to consider the clinical and economic burden posed by CRKP, CRPA, and CRAB when shirting resource allocation \[[@B41-antibiotics-09-00514]\].

The proportions of CRKP, CRPA, and CRAB in the four sampled hospitals were 10.29%, 31.75%, and 56.54%, respectively, which were approximate the national levels reported in China Antimicrobial Resistance Surveillance System (CARSS) (8.03%, 22.61%, and 58.05%) \[[@B42-antibiotics-09-00514]\]. In addition, the mean total hospital cost, length of hospital stay, and hospital mortality were \$3042 and \$2470, 10.1 days and 9.4 days, 0.3% and 0.4% in Zhejiang and Shandong province in 2015, respectively, which were similar to the national levels (\$2378, 9.6 days, and 0.4%). Therefore, we assumed that the antibiotic resistant level, and clinical and economic burden due to CRKP, CRPA, and CRAB from four sampled hospitals in China were approximate results representing the national level.

Our study has some limitations. First, due to the retrospective nature of our study, it is difficult to distinguish infection or colonization, which may underestimate the clinical and economic outcome of carbapenem resistant infection. However, colonization is an important reservoir for bacteria causing infection, therefore, it is important to identify the burden of patients with CRKP, CRPA and CRAB, either infected or colonized, in order to contain the spread of these bacteria. In this study, we explored the clinical and economic outcomes for CRKP, CRPA and CRAB isolation and not specifically infection. Studies on clinical infection or colonization separate should be considered in the future as well. Secondly, this is a retrospective study, inherently resulting in bias and confounding, thus, PSM was conducted to balance potential confounding factors in order to minimize the risk of bias. However, PSM is not without its own limitations, which ignore unmeasured confounders that could potentially impact outcomes. Moreover, although it is a multicenter study that was conducted in four tertiary hospitals, the antibiotic resistant levels and the main indicators approximate the national levels, it is necessary to expand this study to different types of hospitals in different areas in the future. Finally, as we had data between 2013 and 2015 only, Monte Carlo simulations with 1000 iterations were conducted and mean values during the study period were reported. Although study period did not influence the conclusions, future studies with update data are warranted.

5. Conclusions {#sec5-antibiotics-09-00514}
==============

This study underscores the substantial clinical and economic burden associated with CRKP, CRPA, and CRAB in hospitalized patients. The input of more resources to control carbapenem resistance in *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* can be justified both for improving clinical outcomes, and for reducing economic costs, thus maximized benefit with available resources. In addition, urgent need for implementing antibiotic stewardship practices across the continuum of hospital settings will hopefully help to curb the emergency and spread of carbapenem resistance and *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii*.

We want to thank the Center for Health Policy Studies, School of Medicine, Zhejiang University for the assistance in primary data collection.

X.Z. participated in the conception and design of this study, data collection, data analysis, and interpretation of data, drafted and revised the manuscript. C.S.L. participated in the conception and design of the study and helped in the revising the manuscript. X.S. and S.G. performed the data analysis, and interpretation of data, drafted and revised the manuscript. H.D. participated in the conception, design of the study, data collection and interpretation of data, and drafted and revised the manuscript. All authors read and approved the final manuscript.

This work was supported by "Pfizer Investment Co. Ltd. (Burden of multi-drug resistant infections in China and associated risk factors)", "The Fundamental Research Funds of Shandong University", and "The Joint Research Funds for Shandong University and Karolinska Institutet".

The authors declare no conflict of interest.

antibiotics-09-00514-t001_Table 1

###### 

Characteristics of the patients with CRKP and CSKP before and after PSM.

  Baseline Characteristics                              Before PSM     After PSM                                            
  ----------------------------------------------------- -------------- ------------- ---------- ------------- ------------- -------
  Number of inpatient, n                                4328           831                      822           822           
  Age in years, median (range)                          72 (0--100)    73 (0--98)    0.323      70 (0--100)   73 (0--98)    0.602
  Sex male, n (%)                                       2963 (68.46)   554 (66.67)   0.309      554 (67.40)   547 (66.55)   0.714
  Insurance, n (%)                                      3568 (82.44)   658 (79.18)   0.025      644 (78.35)   650 (79.08)   0.718
  Number of diagnosis, median (range)                   6 (1--30)      7 (1--23)     0.129      6 (1--30)     6.5 (1--23)   0.481
  Charlson comorbidity index, median (range)            5 (1--34)      5 (1--18)     0.074      5 (1--24)     5 (1--18)     0.710
  Admission to ICU, n (%)                               503 (11.62)    321 (38.63)   \<0.0001   310 (37.71)   312 (37.96)   0.919
  Surgery, n (%)                                        1106 (25.55)   277 (33.33)   \<0.0001   300 (36.50)   276 (33.58)   0.215
  Myocardial infarction, n (%)                          124 (2.87)     19 (2.29)     0.352      22 (2.68)     19 (2.31)     0.635
  Congestive heart failure, n (%)                       764 (17.65)    121 (14.56)   0.03       125 (15.21)   119 (14.48)   0.677
  Peripheral vascular disease, n (%)                    54 (1.25)      11 (1.32)     0.857      12 (1.46)     11 (1.34)     0.834
  Cerebrovascular diseases, n (%)                       2178 (50.32)   484 (58.24)   \<0.0001   462 (56.20)   476 (57.91)   0.485
  Dementia, n (%)                                       130 (3.00)     24 (2.89)     0.858      23 (2.80)     24 (2.92)     0.882
  Chronic pulmonary disease, n (%)                      1084 (25.05)   154 (18.53)   \<0.0001   139 (16.91)   154 (18.73)   0.334
  Connective tissue disease, n (%)                      83 (1.92)      9 (1.08)      0.096      11 (1.34)     9 (1.09)      0.653
  Mild liver disease, n (%)                             163 (3.77)     24 (2.89)     0.215      25 (3.04)     24 (2.92)     0.885
  Peptic ulcer disease, n (%)                           29 (2.98)      31 (3.73)     0.253      40 (4.87)     31 (3.77)     0.275
  Diabetes mellitus, n (%)                              1206 (27.87)   194 (23.35)   0.007      175 (21.29)   193 (23.48)   0.287
  Diabetes mellitus with chronic complications, n (%)   163 (3.77)     15 (1.81)     0.005      13 (1.58)     15 (1.82)     0.703
  Moderate to severe chronic kidney disease, n (%)      322 (7.44)     102 (12.27)   \<0.0001   116 (14.11)   97 (11.80)    0.163
  Hemiplegia, n (%)                                     38 (0.88)      8 (0.96)      0.812      6 (0.73)      8 (0.97)      0.591
  Solid tumor without metastases, n (%)                 298 (6.89)     52 (6.26)     0.51       59 (7.18)     50 (6.08)     0.372
  Leukemia, n (%)                                       67 (1.55)      24 (2.89)     0.007      27 (3.28)     24 (2.92)     0.670
  Malignant lymphoma, n (%)                             46 (1.06)      15 (1.81)     0.07       19 (2.31)     15 (1.82)     0.488
  Severe liver disease, n (%)                           57 (1.32)      13 (1.56)     0.572      11 (1.34)     13 (1.58)     0.681
  Metastatic tumor, n (%)                               249 (5.75)     16 (1.93)     \<0.0001   15 (1.82)     16 (1.95)     0.856

CRKP: carbapenem resistant Klebsiella pneumoniae, CSKP: carbapenem susceptible K. pneumoniae, PSM: propensity score matching, ICU: intensive care unit.

antibiotics-09-00514-t002_Table 2

###### 

Characteristics of the patients with CRPA and CSPA before and after PSM.

  Baseline Characteristics                              Before PSM     After PSM                                               
  ----------------------------------------------------- -------------- -------------- ---------- -------------- -------------- -------
  Number of inpatient, n                                2674           1244                      1155           1155           
  Age in years, median (range)                          73 (0--100)    79 (0--98)     \<0.0001   77 (0--100)    79 (0--98)     0.994
  Sex male, n (%)                                       1775 (66.38)   877 (70.50)    0.01       803 (69.52)    812 (70.30)    0.683
  Insurance, n (%)                                      2322 (86.84)   1084 (87.14)   0.794      1007 (87.19)   1007 (87.19)   1.000
  Number of diagnosis, median (range)                   6 (1--36)      7 (1--21)      0.002      7 (1--36)      7 (1--21)      0.444
  Charlson comorbidity index, median (range)            5 (1--34)      5 (1--22)      0.007      5 (1--34)      5 (1--22)      0.468
  Admission to ICU, n (%)                               282 (10.55)    283 (22.75)    \<0.0001   252 (21.82)    221 (19.13)    0.110
  Surgery, n (%)                                        554 (20.72)    275 (22.11)    0.322      272 (23.55)    245 (21.21)    0.178
  Myocardial infarction, n (%)                          65 (2.43)      46 (3.70)      0.026      40 (3.46)      40 (3.46)      1.000
  Congestive heart failure, n (%)                       504 (18.85)    196 (15.76)    0.019      192 (16.62)    178 (15.41)    0.427
  Peripheral vascular disease, n (%)                    24 (0.90)      20 (1.61)      0.05       19 (1.65)      17 (1.47)      0.737
  Cerebrovascular diseases, n (%)                       1360 (50.86)   813 (65.35)    \<0.0001   732 (63.38)    735 (63.64)    0.897
  Dementia, n (%)                                       169 (6.32)     86 (6.91)      0.484      82 (7.10)      85 (7.36)      0.810
  Chronic pulmonary disease, n (%)                      1113 (41.62)   292 (23.47)    \<0.0001   268 (23.20)    289 (25.02)    0.307
  Connective tissue disease, n (%)                      55 (2.06)      16 (1.29)      0.092      17 (1.47)      16 (1.39)      0.861
  Mild liver disease, n (%)                             40 (1.50)      23 (1.85)      0.414      21 (1.82)      22 (1.90)      0.878
  Peptic ulcer disease, n (%)                           57 (2.13)      37 (2.97)      0.109      37 (3.20)      33 (2.86)      0.627
  Diabetes mellitus, n (%)                              614 (22.96)    310 (24.92)    0.179      309 (26.75)    291 (25.19)    0.393
  Diabetes mellitus with chronic complications, n (%)   52 (1.94)      23 (1.85)      0.839      21 (1.82)      22 (1.90)      0.878
  Moderate to severe chronic kidney disease, n (%)      191 (7.14)     105 (8.44)     0.153      93 (8.05)      94 (8.14)      0.939
  Hemiplegia, n (%)                                     37 (1.38)      21 (1.69)      0.463      20 (1.73)      20 (1.73)      1.000
  Solid tumor without metastases, n (%)                 117 (4.38)     59 (4.74)      0.605      56 (4.85)      50 (4.33)      0.551
  Leukemia, n (%)                                       21 (0.79)      15 (1.21)      0.199      13 (1.13)      11 (0.95)      0.682
  Malignant lymphoma, n (%)                             17 (0.64)      8 (0.64)       0.979      10 (0.87)      8 (0.69)       0.636
  Severe liver disease, n (%)                           23 (0.86)      9 (0.72)       0.658      11 (0.95)      8 (0.69)       0.490
  Metastatic tumor, n (%)                               70 (2.62)      24 (1.93)      0.19       24 (2.08)      23 (1.99)      0.883

CRKP: carbapenem resistant *Pseudomonas aeruginosa*, CSKP: carbapenem susceptible *P. aeruginosa*, PSM: propensity score matching, ICU: intensive care unit.

antibiotics-09-00514-t003_Table 3

###### 

Characteristics of the patients with CRAB and CSAB before and after PSM.

  Baseline Characteristics                              Before PSM     After PSM                                               
  ----------------------------------------------------- -------------- -------------- ---------- --------------- ------------- -------
  Number of inpatient, n                                1280           1665                      682             682           
  Age in years, median (range)                          73 (0--100)    68 (0--102)    \<0.0001   70.5 (0--100)   71 (0--102)   0.845
  Sex male, n (%)                                       917 (71.64)    1127 (67.69)   0.021      480 (70.38)     480 (70.38)   1.000
  Insurance, n (%)                                      1030 (80.47)   1167 (70.09)   \<0.0001   500 (73.31)     510 (74.78)   0.537
  Number of diagnosis, median (range)                   6 (1--23)      6 (1--24)      0.02       6 (1--23)       6 (1--24)     0.243
  Charlson comorbidity index, median (range)            5 (1--28)      4 (1--18)      \<0.0001   5 (1--16)       5 (1--17)     0.352
  Admission to ICU, n (%)                               160 (12.50)    825 (49.55)    \<0.0001   160 (23.46)     170 (24.93)   0.527
  Surgery, n (%)                                        380 (29.69)    753 (45.23)    \<0.0001   250 (36.66)     246 (36.07)   0.822
  Myocardial infarction, n (%)                          34 (2.66)      47 (2.82)      0.784      24 (3.52)       22 (3.23)     0.764
  Congestive heart failure, n (%)                       250 (19.53)    247 (14.83)    0.001      115 (16.86)     123 (18.04)   0.568
  Peripheral vascular disease, n (%)                    21 (1.64)      36 (2.16)      0.309      20 (2.93)       18 (2.64)     0.742
  Cerebrovascular diseases, n (%)                       676 (52.81)    1002 (60.18)   \<0.0001   389 (57.04)     380 (55.72)   0.623
  Dementia, n (%)                                       42 (3.28)      41 (2.46)      0.183      33 (4.84)       21 (3.08)     0.096
  Chronic pulmonary disease, n (%)                      342 (26.72)    306 (18.38)    \<0.0001   138 (20.23)     163 (23.90)   0.103
  Connective tissue disease, n (%)                      21 (1.64)      22 (1.32)      0.474      10 (1.47)       6 (0.88)      0.314
  Mild liver disease, n (%)                             42 (3.28)      56 (3.36)      0.902      26 (3.81)       22 (3.23)     0.557
  Peptic ulcer disease, n (%)                           34 (2.66)      51 (3.06)      0.513      21 (3.08)       20 (2.93)     0.874
  Diabetes mellitus, n (%)                              295 (23.05)    354 (21.26)    0.247      160 (23.46)     152 (22.29)   0.606
  Diabetes mellitus with chronic complications, n (%)   39 (3.05)      19 (1.14)      \<0.0001   10 (1.47)       14 (2.05)     0.410
  Moderate to severe chronic kidney disease, n (%)      100 (7.81)     160 (9.61)     0.088      61 (8.94)       54 (7.92)     0.495
  Hemiplegia, n (%)                                     15 (1.17)      31 (1.86)      0.134      12 (1.76)       11 (1.61)     0.833
  Solid tumor without metastases, n (%)                 121 (9.45)     72 (4.32)      \<0.0001   32 (4.69)       45 (6.60)     0.127
  Leukemia, n (%)                                       18 (1.41)      4 (0.24)       \<0.0001   2 (0.29)        3 (0.44)      1.000
  Malignant lymphoma, n (%)                             13 (1.02)      7 (0.42)       0.051      1 (0.15)        3 (0.44)      0.624
  Severe liver disease, n (%)                           15 (1.17)      25 (1.50)      0.444      11 (1.61)       6 (0.88)      0.222
  Metastatic tumor, n (%)                               94 (7.34)      26 (1.56)      \<0.0001   12 (1.76)       21 (3.08)     0.113

CRKP: carbapenem resistant *Acinetobacter baumannii*, CSKP: carbapenem susceptible *A. baumannii*, PSM: propensity score matching, ICU: intensive care unit.
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###### 

Economic costs of patients with CRKP and CSKP after PSM for potential confounding variables.

  Hospital Cost (\$)    CSKP     CRKP     Difference   *p*-Value                                                
  --------------------- -------- -------- ------------ ----------- -------- -------- -------- -------- -------- ----------
  Total hospital cost   21,229   21,005   21,453       35,480      35,149   35,811   14,252   13,852   14,653   \<0.0001
  Antibiotic cost       2878     2824     2932         6175        6097     6252     3296     3202     3390     \<0.0001
  Medication cost       10,081   9960     10,202       19,213      19,027   19,399   9132     8910     9354     \<0.0001
  Diagnostic cost       2868     2836     2900         4385        4343     4426     1517     1465     1570     \<0.0001
  Treatment cost        5112     5047     5176         7686        7595     7776     2574     2462     2686     \<0.0001
  Material cost         3096     3051     3140         3993        3937     4050     899      826      971      \<0.0001
  Other cost            70       68       73           62          62       64       −8       −11      −5       0.0028

CRKP: carbapenem resistant *Klebsiella pneumoniae*, CSKP: carbapenem susceptible *K. pneumoniae*, PSM: propensity score matching, UI: uncertainty interval.
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###### 

Economic costs of patients with CRPA and CSPA after PSM for potential confounding variables.

  Hospital Cost (\$)    CSPA     CRPA     Difference   *p*-Value                                          
  --------------------- -------- -------- ------------ ----------- -------- -------- ------ ------ ------ ----------
  Total hospital cost   20,908   20,670   21,146       25,508      25,244   25,771   4605   4249   4960   \<0.0001
  Antibiotic cost       2426     2380     2472         3504        3450     3558     1078   1007   1149   \<0.0001
  Medication cost       10,082   9959     10,203       13,135      12,996   13,273   3053   2867   3238   \<0.0001
  Diagnostic cost       2759     2728     2790         3129        3094     3163     370    323    416    0.0001
  Treatment cost        5512     5434     5591         6683        6578     6789     1174   1043   1305   \<0.0001
  Material cost         2397     2354     2440         2472        2435     2508     76     19     132    \<0.0001
  Other cost            62       60       63           84          81       87       23     19     26     0.3252

CRKP: carbapenem resistant *Pseudomonas aeruginosa*, CSKP: carbapenem susceptible *P. aeruginosa*, PSM: propensity score matching, UI: uncertainty interval.
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###### 

Economic costs of patients with CRAB and CSAB after PSM for potential confounding variables.

  Hospital Cost (\$)    CSAB     CRAB     Difference   *p*-Value                                          
  --------------------- -------- -------- ------------ ----------- -------- -------- ------ ------ ------ ----------
  Total hospital cost   20,349   20,103   20,595       27,630      27,342   27,919   7277   6897   7657   \<0.0001
  Antibiotic cost       2380     2331     2428         3917        3868     3965     1537   1468   1605   \<0.0001
  Medication cost       9160     9036     9283         13,065      12,948   13,183   3902   3731   4074   \<0.0001
  Diagnostic cost       2840     2809     2870         3468        3439     3497     628    585    670    \<0.0001
  Treatment cost        5155     5073     5237         7313        7143     7482     2156   1967   2344   \<0.0001
  Material cost         3102     3050     3153         3521        3473     3569     421    351    491    \<0.0001
  Other cost            91       89       93           93          90       96       2      −2     6      0.0001

CRAB: carbapenem resistant *Acinetobacter baumannii*, CSAB: carbapenem susceptible *A. baumannii*, PSM: propensity score matching, UI: uncertainty interval.

antibiotics-09-00514-t007_Table 7

###### 

Length of stay among patients with CRKP and CSKP, among patients with CRPA and CSPA, and among patients with CRAB and CSAB after PSM for potential confounding variables.

  Length of Stay (Days)   Carbapenem Susceptible-   Carbapenem Resistant-   Difference   *p*-Value                                      
  ----------------------- ------------------------- ----------------------- ------------ ----------- ------ ------ ------ ------ ------ ----------
  CRKP vs. CSKP           32.9                      32.6                    33.2         46.1        45.7   46.5   13.2   12.7   13.7   \<0.0001
  CRPA vs. CSPA           41.1                      40.6                    41.6         46.5        45.6   47.4   5.4    4.4    6.5    0.0003
  CRAB vs. CSAB           33.7                      33.4                    34.1         49.6        47.7   51.4   15.8   13.9   17.7   0.0004

CRKP: carbapenem resistant *Klebsiella pneumoniae*, CSKP: carbapenem susceptible *K. pneumoniae*, CRKP: carbapenem resistant *Pseudomonas aeruginosa*, CSKP: carbapenem susceptible *P. aeruginosa*, CRAB: carbapenem resistant *Acinetobacter baumannii*, CSAB: carbapenem susceptible *A. baumannii*, PSM: propensity score matching, UI: uncertainty interval.
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###### 

In hospital mortality among patients with CRKP and CSKP, among patients with CRPA and CSPA, and among patients with CRAB and CSAB after PSM for potential confounding variables.

  In Hospital Mortality Rate (%)   Carbapenem Susceptible-   Carbapenem Resistant-   Difference   *p*-Value                                      
  -------------------------------- ------------------------- ----------------------- ------------ ----------- ------ ------ ------ ------ ------ -------
  CRKP vs. CSKP                    6.65                      6.43                    6.87         9.59        9.33   9.85   2.94   2.6    3.28   0.024
  CRPA vs. CSPA                    4.73                      4.54                    4.91         6.77        6.55   6.99   2.03   1.75   2.32   0.052
  CRAB vs. CSAB                    4.25                      4.07                    4.43         8.28        8.04   8.53   4.03   3.73   4.33   0.003

CRKP: carbapenem resistant *Klebsiella pneumoniae*, CSKP: carbapenem susceptible *K. pneumoniae*, CRKP: carbapenem resistant *Pseudomonas aeruginosa*, CSKP: carbapenem susceptible *P. aeruginosa*, CRAB: carbapenem resistant *Acinetobacter baumannii*, CSAB: carbapenem susceptible *A. baumannii*, PSM: propensity score matching, UI: uncertainty interval.
